On January 30, Forbes China revealed its list of emerging unicorns in China for 2022. Forbes China tracked more than 2,000 startups that raised more than RMB 200 million or USD 30 million in a single round of funding in the past year and are likely to cross over into the unicorn category.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.

Roche Diagnostics plans to bring a fully automated mass spectrometry-based clinical analyzer to market in 2024.

After three years, China announced its reopening from January 8, 2023. Passengers can enter China without quarantine. All you need is a negative PCR result within 48 hours before departure. You do not need to apply for a health code.

Beckman Coulter Diagnostics announced on Tuesday that it has entered a strategic partnership with Israeli diagnostic company MeMed to develop and commercialize a host immune response diagnostic test.

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2022.

On January 31, A-share listed Daan Gene released the 2022 full-year performance forecast.

Precision oncology company Guardant Health announced on Monday that FDA has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic.

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.

Easy Diagnosis released a performance preview on the evening of January 30, expecting 2022 net profit attributable to shareholders of listed companies of CNY4.6 billion to CNY5 billion, an increase of 225.5% to 253.8%; basic earnings per share of about CNY29.99 to CNY32.60.

GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, reported financial results for the fourth quarter and full year ended December 31, 2022.

Danaher Corporation (NYSE: DHR) (the "Company") announced results for the fourth quarter and full year 2022. All results in this release reflect only continuing operations unless otherwise noted. Net earnings refers to net earnings attributable to common shareholders.

On the evening of January 19, Andon Health Co., Ltd. released the 2022 performance forecast, and it is expected that the company's net profit in 2022 will be 16.5 billion CNY to 17.5 billion CNY, a year-on-year increase of 1715.9% to 1825.95%.

Johnson & Johnson announced results for fourth-quarter and full year 2022.

Abbott announced financial results for the fourth quarter ended Dec. 31, 2022.